Rexgenero Presents Update on Phase III Clinical Trials with REX-001, a Cell-based Therapy for Critical Limb Ischaemia

Rexgenero presented an update on its two Phase III SALAMANDER trials being conducted across Europe for its cell-based therapy, REX-001, which aims to treat critical limb ischaemia (CLI) in diabetic patients. During Rexgenero’s presentation at the Cell and Gene Therapy Meeting in Barcelona, organised by the Alliance for Regenerative Medicine, Joe Dupere, CEO provided an update on the Phase III trial of REX-001. Twelve of the 25 planned trial sites are now open and...

Diabetes drug Jardiance reverses heart failure in animal model – ketogenic diet likely provides the same benefit with less risk

Researchers at Mount Sinai Icahn School of Medicine in New York have shown in a pig model of heart failure, that after two months on the drug, markers of heart function improved dramatically. In a placebo-controlled study of 14 pigs with heart failure, cardiac magnetic resonance and 3D-echocardiography were used to observe what was happening in the animals’ hearts. They observed improved heart function in the treated pigs - reductions in pulmonary congestion,...

Anti obesity gene variant discovered – future target for treatment of obesity?

In a study published today, researchers at the Wellcome Trust-MRC institute of Metabolic Science in Cambridge appear to have identified a series of MC4R gene variants that modulate the signals in the brain that determine when the person 'feels full'. These findings solidify the idea that some people are simply 'naturally skinny'. The study covered approximately 0.5 million people in the UK biobank, and looked at genetic associations to weight, type 2 diabetes, and...